Current Impact and Application of Abuse-Deterrent Opioid Formulations in Clinical Practice

被引:1
|
作者
Lee, Ya-Han [1 ]
Brown, Daniel L. [2 ]
Chen, Hsiang-Yin [1 ,3 ]
机构
[1] Taipei Med Univ, Sch Pharm, Dept Clin Pharm, 250 Wu Hsin St, Taipei, Taiwan
[2] Calif Hlth Sci Univ, Coll Pharm, Clovis, CA USA
[3] Taipei Med Univ, Wan Fang Hosp, Dept Pharm, Taipei, Taiwan
关键词
Opioid abuse; abuse-deterrent formulations; ADF; post-marketing; FDA guidance; cost impact; abuse liking; physician attitude; generic abuse-deterrent formulation; clinical application; TAMPER-RESISTANT FORMULATIONS; EXTENDED-RELEASE HYDROCODONE; UNITED-STATES; CHRONIC PAIN; DOUBLE-BLIND; POSTOPERATIVE PAIN; SUBSTANCE-ABUSE; RISK-EVALUATION; NONMEDICAL USE; SINGLE-ENTITY;
D O I
暂无
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Background: Abuse-deterrent formulations (ADFs) represent one novel strategy for curbing the potential of opioid abuse. Objective: We aim to compare and contrast the characteristics and applications of current abuse-deterrent opioid products in clinical practice. Methods: Literature searches were conducted in databases (Pubmed Medline, International Pharmaceutical Abstracts, Google Scholar) and official reports. Relevant data were screened and organized into: 1) epidemiology of opioid abuse, 2) mitigation strategies for reducing opioid abuse, 3) development of ADFs, and 4) clinical experience with these formulations. Results: Increasing trends of opioid abuse and misuse have been reported globally. There are 5 types of abuse-deterrent opioid products: physical chemical barrier, combined agonist/antagonist, sequestered aversive agent, prodrug, and novel delivery system. The advantages and disadvantages of the 5 options are discussed in this review. A total of 9 products with abuse-deterrent labels have been approved by the Food and Drug Administration (FDA). The rates of abuse, diversion, and overdose deaths of these new products are also discussed. A framework for collecting in-time data on the efficacy, benefit and risk ratio, and cost-effectiveness of these new products is suggested to facilitate their optimal use. Limitations: The present review did not utilize systematic review standards or meta-analytic techniques, given the large heterogeneity of data and outcomes reviewed. Conclusions: ADFs provide an option for inhibiting the abuse or misuse of oral opioid products by hindering extraction of the active ingredient, preventing alternative routes of administration, or causing aversion. Their relatively high costs, uncertain insurance policies, and limited data on pharmacoeconomics warrant collaborative monitoring and assessment by government agencies, pharmaceutical manufacturers, and data analysis services to define their therapeutic role in the future.
引用
收藏
页码:E1003 / E1023
页数:21
相关论文
共 50 条
  • [1] Abuse-deterrent Opioid Formulations
    Litman, Ronald S.
    Pagan, Olivia H.
    Cicero, Theodore J.
    ANESTHESIOLOGY, 2018, 128 (05) : 1015 - 1026
  • [2] Abuse-Deterrent Opioid Formulations
    Abramowicz, Mark
    Zuccotti, Gianna
    Pflomm, Jean-Marie
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 314 (16): : 1744 - 1745
  • [3] Abuse-Deterrent Opioid Formulations
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2015, 57 (1476): : 119 - 121
  • [4] Review of Opioid Abuse-Deterrent Formulations: Impact and Barriers to Access
    Webster, Lynn
    Gudin, Jeffrey
    JOURNAL OF PAIN RESEARCH, 2024, 17 : 1989 - 2000
  • [5] Safety and performance of current abuse-deterrent formulations
    Ahmad, Rand
    Alaei, Samaneh
    Omidian, Hamid
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2018, 14 (12) : 1255 - 1271
  • [6] Mitigation of IV Abuse Through the Use of Abuse-Deterrent Opioid Formulations: An Overview of Current Technologies
    Rauck, Richard L.
    PAIN PRACTICE, 2019, 19 (04) : 443 - 454
  • [7] Abuse-Deterrent Opioid Formulations #329
    O'Neill, Ryann
    Lor, Kimberly
    Pruskowski, Jennifer
    JOURNAL OF PALLIATIVE MEDICINE, 2017, 20 (06) : 676 - 678
  • [8] Are abuse-deterrent opioid formulations all they are crushed up to be?
    Nelson, Lewis S.
    ADDICTION, 2019, 114 (03) : 401 - 402
  • [9] Challenges Involved in the Development and Delivery of Abuse-deterrent Formulations of Opioid Analgesics
    Cohen, Joshua P.
    Mendoza, Mario
    Roland, Carl
    CLINICAL THERAPEUTICS, 2018, 40 (02) : 334 - 344
  • [10] Abuse-Deterrent Opioid Formulations and the Opioid Crisis: A Pharmacist's Perspective
    Gadd, Shannon
    Cox, Nicholas
    Samuelson, James
    Kenney, Amy
    Turner, Kyle
    Cochran, Gerald
    THERAPEUTIC DRUG MONITORING, 2021, 43 (01) : 35 - 41